Holistic cancer genome profiling for every patient

Nik-Zainal Serena, Memari Yasin, Davies Helen R.

* MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, UK

Correspondence: Serena Nik-Zainal, MD, MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Box 197, Cambridge Biomedical Research Campus, CB2 0XZ, Cambridge UK, Snz@mrc-cu.cam.ac.uk

**Review article: Biomedical intelligence | Published 13 January 2020 | doi:10.4414/smw.2019.20158**

Cite this as: Swiss Med Wkly. 2020;150:w20158

Summary

Technological advances in the ability to read the human genome have accelerated the speed of sequencing, such that today we can perform whole genome sequencing (WGS) in one day. Until recently, genomic studies have largely been limited to seeking novel scientific discoveries. The application of new insights gained through cancer WGS into the clinical domain, have been relatively limited. Looking ahead, a vast amount of data can be generated by genomic studies. Of note, excellent organisation of genomic and clinical data permits the application of machine-learning methods which can lead to the development of clinical algorithms that could assist future clinicians and genomicists in the analysis and interpretation of individual cancer genomes. Here, we describe what can be gleaned from holistic whole cancer genome profiling and argue that we must build the infrastructure and educational frameworks to support the modern clinical genomicist to prepare for a future where WGS will be the norm.

**Keywords:** genomics, genomic profiling, mutational signatures, patient stratification, machine-learning

Introduction

The development of sequencing-by-synthesis [1] catapulted the field of genomics into a new age. The ability to immobilise each DNA molecule on the surface of a chip and continuously read each nucleotide from every DNA molecule as a result of novel “reversible” terminator chemistry increased the speed and scale of sequencing by orders of magnitude [1]. The term “massively parallel sequencing” (MPS) was coined. Today, we can sequence a whole human genome in one day.

When studying cancer genomics of solid tumours, two samples are required per cancer patient; a DNA sample from the cancer (“tumour”) DNA representative of the cancer clone and a DNA sample extracted from peripheral blood lymphocytes (“normal”) DNA derived from a heterogeneous cellular population representative of the germline genome. Sequencing tumour and normal DNA allows the identification of “somatic mutations”, those which are acquired and present only in the cancer and not the germline. The two DNA samples from each patient are subjected to fragmentation independently, each generating billions of DNA fragments. Size-selection of a fragment size of interest is performed, usually 400–600 base pairs for a whole genome. Around 150 nucleotides at each end of the size-selected fragments are sequenced using MPS technology. The aim is for each of the 3,000,000,000 base pairs present in the human genome to be re-sequenced at least 30 times on average. This strategy, called paired-end high-coverage sequencing, is a general principle that can be adapted (e.g., single-ended sequencing, 75 or 100 base-pair read lengths and/or variable fragment sizes). In a whole genome sequencing (WGS) experiment, the entire human genome is captured. In a whole exome sequencing (WES) experiment, protein-coding sequences are captured (~1.5% of the genome). Targeted sequencing experiments tend to encompass genes of interest and a raft of other loci that may be informative (e.g., gene fusions and copy number alterations) (~0.1%) or less of the genome. In terms of sequencing costs, WGS is the most expensive and targeted experiments are cheapest. There are also associated costs of storage, computing and analysis to consider.

What we obtain in terms of genomics depends on the sequencing experiment. When a WGS is performed, one obtains “driver” mutations – causally implicated mutations of carcinogenesis, passenger variants, structural variants, copy number aberrations and many other insights into the noncoding genome [2, 3]. Other sequencing experiments may be cheaper but limited to only driver mutations [4] or selected patterns (table 1). Although there have been great efforts to enhance these panels [5], one will only see what one is looking for. Opportunities for new discoveries are limited.

In this review, we highlight what else can be seen in the whole human cancer genome and why it might be useful clinically. As we look towards a future when genomics may become a standard part of cancer diagnostics, we highlight current issues and how we should tackle them going forward.

Whole cancer genomes

**Driver mutations in cancer**

Decades of cancer research were focused on discovery of driver mutations, positively-selected genetic changes that occur in “cancer genes”, because these became targets for developing new therapeutic agents [6–9]. A key contribution of MPS, in the earlier part of the 21st century, was the acceleration of novel cancer gene discovery [10]. Improved sequencing affordability resulted in more cancers...
being sequenced per experiment. Thus, rare, low-frequen-
cy cancer genes present in common cancers [4, 10–15],
as well as common cancer genes present in rare cancers
[16, 17], were increasingly identified. These studies also
revealed that there was an enormous amount of inter-tu-
mour heterogeneity between patients, with most patients
having different combinations of a long list of drivers even
when they shared the same tumour type [4]. Hence, using
individual driver mutations or cancer genes as a strategy to
develop therapeutic targets is likely to be of limited suc-
cess. Given that there are many hundreds of driver muta-
tions / cancer genes and a mere handful of successfully de-
veloped targeted therapies that are clinically available after
four decades of cancer research, we need to find alternative
strategies to treat cancers more effectively.

Passenger mutations: a resource of historical informa-
tion
Notably, cancers contain far more than the handful of dri-
vers, estimated to be between one to ten per tumour [6,
8]. Each cancer carries thousands of “passenger” mutations
that have historically been thought of as unimportant, in-
consequential mutational noise [6]. However, they are in
fact a mine of information, reporting the biological history
of the tumour [2, 18, 19]. The catalogue of somatic mu-
tations that is revealed through cancer sequencing is the
final outcome of the mutational processes that have oc-
curred through malignant transformation [2, 18, 19]. Each
mutational process leaves its characteristic imprint or mu-
tational signature on the cancer genome, defined by the
mechanisms of DNA damage and DNA repair of which it
is comprised [2, 18, 19]. Whatever the nature of the mu-
tational process, the final set of mutations, be they sub-
stitutions, insertions/deletions or structural variation, is al-
so determined by the strength and duration of exposure to
each mutational process [2, 18, 19]. Some exposures may
be weak or moderate in intensity, whereas others may be
strong in their effect [19]. Similarly, some exposures might
be on-going through the entire lifetime of the patient, even
preceding the formation of the cancer, and some may start
or become dominant later in tumorigenesis [19].

WGS experiments permitted us to use mathematical meth-
ods to distil the mutational signatures buried within these
cancers. In 2012, using WGS data from just 21 breast can-
cers, the first five mutational signatures were revealed [2].
Subsequently, similar approaches were used to unearth at
least 21 different mutation signatures across 30 different
cancer types [18]. This included signatures associated with
past exposure to environmental carcinogens, such as tobac-
co smoke in lung cancer and ultraviolet radiation in ma-
lignant melanoma, and endogenous sources of mutagene-
sis including ubiquitous deamination at methyl-cytosines
seen in nearly all human cancers and the activity of other
dysregulated proteins such as polymerase epsilon (POLE).

Table 1: Data obtainable from various sequencing experiments.

<table>
<thead>
<tr>
<th>Drivers</th>
<th>Whole genome sequencing</th>
<th>Whole exome sequencing</th>
<th>Targeted sequencing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copy number drivers (amplifications and homozygous deletions)</td>
<td>Comprehensive</td>
<td>Semi-reliable</td>
<td>Limited to genes on panel and not always reliable</td>
</tr>
<tr>
<td>Mutational signatures</td>
<td>Comprehensive</td>
<td>Limited</td>
<td>Not reliable</td>
</tr>
<tr>
<td>Complex rearrangements</td>
<td>Comprehensive</td>
<td>Not reliable</td>
<td>Not detectable</td>
</tr>
<tr>
<td>Copy number aberrations</td>
<td>Comprehensive</td>
<td>Semi-reliable</td>
<td>Not detectable</td>
</tr>
<tr>
<td>Germline variation</td>
<td>Comprehensive</td>
<td>High-penetration alleles</td>
<td>Limited</td>
</tr>
<tr>
<td>Phylogenetic trees</td>
<td>Possible. Limited branching unless very high-depth</td>
<td>Possible</td>
<td>Limited</td>
</tr>
</tbody>
</table>

It should be noted that these are early days in this field. It
was initially focused almost exclusively on substitutions,
whereas today there are mutational signatures reported for
insertions/deletions (though not verified or widely taken
up so far) [22], structural variation [23] and copy number
aberrations [24]. Indeed, even the total tally of substitution
signatures is not static. In excess of 40 signatures have
been reported [22], although this is expected to change as
more cancers are sequenced in the future and as methods
and thinking evolve on these concepts.

Other angles
WGS also permits other findings to be revealed including
gene fusion events and retrotransposition-driven genetic
changes [25]. There remains much to learn about 3D compac-
tion of the human genome [26, 27], enhancer [28] and
promoter mutations [29] and the consequences of complex
rerrangements in the genome [30], including the forma-
tion of micronuclei [31]. WGS data also contain informa-
tion about immunogenicity of the tumour, including human
leucocyte antigen (HLA) and T-cell receptor information
[32, 33].

Quite apart from the somatic cancer genome, there is a
germine genome, which reportedly sets our lifetime risk
of cancer [34], modifiable by the variety of lifestyle factors
that we are exposed to. Currently, we know very little about
how the germine genome interacts with or influences
somatic mutation acquisition [28, 35]. Unlike acquired
mutations, there are well-known inherited predisposi-
tion genes that have significant implications for relatives
if identified as a new finding in a cancer patient [23, 36].
There are also a variety of moderate-penetrate and low-
penetration genetic alleles that when combined can provide
measures of cancer risk called polygenic risk scores [34, 37].
How these data from WGS can be used effectively for
clinical application remains unknown. It is likely to be-
come clearer with the increasing availability of WGS in the
near future.

Beyond the genome, there is the transcriptome and methy-
lome, presenting additional layers of data per patient. As
a scientific community, we are still learning how best to
integrate these data. The areas of metabolomics and pro-

[0x0]
teomics are also coming to the fore. We may look forward to a future where these different modalities are available across each cancer, providing very rich datasets from which to learn.

**Tumour phylogenies**

Another area of particular growth has been the study of the phylogenetic evolution of cancers [3]. Tumour evolutionary histories or phylogenies can be constructed by taking multiple samples per patient, separated either by space [38, 39] (multiple primaries, or multiple sites per primary) or by time [40] (e.g., primary and metastasis). The digital nature of modern sequencing technology also permits estimation of subpopulations of cells within a single cancer sample [3].

For a sample with sequence coverage of 40-fold, this implies that sequence data from approximately 40 DNA molecules are available at any particular genomic coordinate, on average. If the sample were representative of the germline, a heterozygous variant of a diploid chromosome would be expected to be present in approximately 50% of reads (~20 reads), whereas a homozygous variant should be present in 100% of reads. For a tumour sample, a fraction of reads will come from normal cells such as lymphocytes or stromal tissue, but the remaining reads should be representative of the tumour. A heterozygous variant in a diploid chromosome in the tumour genome should be present in half of the remaining reads, whatever that may be. Thus, if there was an estimated 70% tumour cellularity, then a heterozygous mutation would be present at 35% variant allele fraction. When collections of mutations do not abide by this rule and are instead consistently present in a subset of the expected fraction of reads, this can be used to infer the presence of a subclonal populations in a cancer [3]. Numerous mathematical methods have been developed to identify such subpopulations [3, 41]. Phylogenetic trees of each primary cancer can therefore be constructed to a finite level of resolution.

What these studies have collectively shown us is that cancers may begin as a clonal outgrowth but inevitably evolve under the pressure of environmental changes, with resultant subclonal populations in due course. Intra-tumour heterogeneity is in fact the norm.

**Insights from latest technology: adjustments to a biological perspective**

Recent advancements in sequencing technology, including low-volume and single-cell sequencing, have led us to gain some fascinating new insights [42, 43] that may require us to reflect and adjust our understanding of cancer biology.

First, the concept of “driver mutations” requires re-thinking. In the past, we could see these drivers in cancers and assumed that they were causally implicated in tumorigenesis because of observed enrichment of these mutations in particular cancers, such as TP53 (tumour protein p53) in breast cancer, APC (adenomatous polyposis coli) in colorectal cancer and KRAAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homologue) in pancreatic cancer. The application of MPS to normal, noncancerous tissues, however, demonstrates that there are “drivers” in all normal tissues too [42–45]. In some instances, some “driver” mutations are more frequent in normal tissues than cancer tissues [42].

Second, not only do normal tissues have these “drivers”, they are present as clonal populations [42–45]. Having multiple clones present in what is nonmalignant, healthy tissue is now increasingly accepted as the norm. There is current debate as to whether these numerous clones in healthy tissues are arising through neutral drift or whether they arise due to selective pressure, and this remains unresolved. Perhaps what we have thought of as “drivers” in cancer are simply the genes that are most frequently mutated in certain tissues and do not confer any driver potential at all. It is possible that some of these alleged driver mutations could be relatively harmless and without effect initially, but as a tissue becomes more awry, it may assert intrinsic potential under selective pressure and become more like a true driver – in other words, their physiological effects are dynamic [42–45]. It is known that some tumour suppressor driver mutations can be reverted back to being normal during tumour evolution [46]. It is thus not inconceivable that in a complex, dynamic cell an alleged driver mutation could evolve to increase the strength of its properties too. This reflection is not simply an academic one; it has implications for clinical trials that rely on driver mutations in a binary way, to stratify patients into respective arms when they may in fact not be the sort of drivers that we had initially believed them to be.

Third, it has also been observed that the burden of mutation in normal tissues matches that of cancers [42–45]. Thousands and tens of thousands of mutations can be present in normal skin cells for example [43]. Statistical studies have suggested that the majority of mutations arise before the transformation into a frank malignancy [44]. For example, exposure to ultraviolet light damage in skin, tobacco damage in lung cells and deamination of methyl-cytosines – all of these create mutational signatures and may even result in heavy, widespread mutagenesis in normal cells. Therefore, we arrive at a critical juncture: given what we can see in normal cells, what are the drivers and mutational signatures that are truly clinically important to recognise?

**Identifying clinically useful genomic properties**

We do not have all the answers at this point in time about which are the clinically meaningful genomic features. That is largely because we have not historically captured all the necessary genomic information to be able to answer these questions. The vast majority of genomics-informed clinical trials have used either single driver events or targetted panels for stratification. Separately, large genomic studies like The Cancer Genome Atlas (TCGA) [11–15] and International Cancer Genome Consortium (ICGC) [2, 23, 47, 48] endeavours have focused on either WES or WGS with some additional modalities such as transcriptomics or methylation studies, but well-annotated clinical data have been lacking. Although it has been immensely valuable to study these cohorts to gain biological understanding, what we need to do for the future is to collect as much of the most comprehensive genomic data as possible, to structure and store the data in modern, intelligent ways, and to learn and relearn from these extensive data as effectively as possible.
Quite apart from identifying driver events, mutational signatures, for example, will reveal a panoply of insults including prior exposures to environmental genotoxins such as tobacco smoke or ultraviolet light \[18, 20\]. Although this is valuable to understand, for an individual patient the signatures of these environmental agents report a past exposure and there is little that we can do to remedy what has already been acquired. Thus, although it is interesting, revealing and has public-health implications, identifying signatures of environmental agents is less clinically useful in terms of intervention for the patient – at least for now.

What is more useful is to identify mutational signatures from biological processes that are on-going, because they may indicate a dysfunctional pathway that is potentially targetable. Examples of defective DNA repair pathways that are clinically informative are mismatch repair (MMR) deficiency \[49\] and BRCA1/BRCA2 deficiency \[36\] (fig. 1). Tumours that have the former are treatable with checkpoint inhibitors whereas those that have the latter have been reported to be particularly sensitive to poly-ADP-ribose inhibitors (PARPi) through synthetic lethal mechanisms, where a tumour is fully-dependent on the normal functioning of PARP because BRCA1 and BRCA2 are no longer operational. Deficiencies in MMR and BRCA1/BRCA2 cause mutagenesis directly and their corresponding signatures can be used as biomarkers to report those deficiencies, making tumours that carry those signatures clinically targetable.

Other endogenous mutational processes may also report biological abnormalities, even if in an indirect way. These are a little more difficult to ascertain and require extensive analytics in order to identify, to “train” using mathematical methods and to apply across cancers in order to develop into some form of biomarker. For example, the mutational signatures associated with the activity of the APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) family of enzymes are characterised by a C>T transition (signature 2) and/or C>G transversion (signature 13) at cytosines that are almost always preceded by a thymine (otherwise described as a TpC sequence context) \[2, 18\]. The first mechanistic step in generating this signature is the deamination of cytosines at TpC contexts to

Figure 1: Holistic cancer genome profiling. Whole cancer genome profiles of four breast cancer patients. Circos plots showing the chromosomal ideogram on the outermost ring, clockwise chr1-chr22,X,Y. Subsequent circles heading inwards: Substitutions as dots plotted on log scale of intermutation distance, small insertions/deletions, copy number (pink = losses, green = gains), rearrangements = lines (green = tandem duplications, pink = large deletions, blue = inversions, grey = translocations). Top right panel depicts substitution mutational signatures, next one below showing indel classes, next one below showing rearrangements. Last panel bottom right shows curated driver mutations. (A) Oestrogen receptor positive breast cancer with good outcome: a tumour with sparse mutagenesis, low numbers of substitutions, indels and rearrangements, mainly signatures 1 and 5. 1q gain and 16q loss are common. (B) Characteristic BRCA1 null tumour with high levels of substitution signature 3, deletions with microhomology, multiple copy number losses and tandem duplications throughout the genome. (C) Mismatch repair deficient tumour with high numbers of signatures 6 and 26, and a very large number of indels at polynucleotide repeat tracts. (D) Mixed APOBEC-mutated and mismatch repair deficiency demonstrating that tumours can have multiple mutational processes.
form uracils, which can only occur when DNA is single stranded (ssDNA). The APOBEC signature tends to show many mutations happening on the same strand (strandedness) [50] for relatively long stretches in the genome (tens of kilobases) suggesting that long spools of ssDNA are available for APOBEC deamination during tumorigenesis. This may perhaps be an indicator of replication stress for the tumour. It consequently follows that tumours that have a preponderance of APOBEC mutagenesis may be tumours that are under a high level of replication stress and may be selectively sensitive to drugs that have been developed for this cause, including WEE1 G2 checkpoint kinase (WEE1) and ATR serine/threonine kinase (ATR) inhibitors.

The value of having a total genomic picture of each cancer through WGS is that it can reveal all that is awry within each tumour. A tumour is, after all, a biological entity that rarely falls into binary categories. A tumour could have a selection of “drivers” which impair diverse pathways in different ways, as well as a selection of mutational signatures occurring in unison such as signatures of APOBEC and MMR deficiency (see fig. 1). Accordingly, to report on such a tumour, and to learn and understand why any individual tumour responds to a particular set of therapeutics or otherwise, we need to be able to interpret whole cancer genomes in a holistic way.

Moreover, to make interpretation of WGS cancers easier and assist clinicians of the future in using WGS cancer data more effectively, it is of enormous utility to develop algorithms or predictors of biological abnormalities and to test these in clinical populations. As an example, we have pioneered the development of a mutational-signature-based algorithm, capable of predicting BRCA1/BRCA2 deficiency, called HRDetect [36]. Critically, it identified many additional breast cancer patients with germline and somatic mutations of BRCA1/BRCA2, promoter hypermethylation of BRCA1, in patients not previously prioritised for BRCA1/BRCA2 screening [36]. Crucially, it also revealed a cohort of women with clear BRCA1/BRCA2-like tumours, but in whom we could not identify the underlying genetic or epigenetic driver [36]. These patients would be missed using current assays such as targeted BRCA1/BRCA2 sequencing and/or possibly the “genomic scars” test. There are thus benefits to taking the mutational signatures approach in identifying these patients.

To convince the clinical research community that these machine-learning-based algorithms are of value, algorithms such as HRDetect must be validated in alternative cohorts and their ability to relate to clinical outcome must be evaluated. Indeed, HRDetect has been applied to a population-based study in Sweden, called SCAN-B [51], in which all women in the south of Sweden with breast cancer are invited to participate in the study without exception. Focusing on a type of breast cancer associated with poor outcomes called triple negative breast cancer (TNBC), all available tumours between 2010–2015 have been whole genome sequenced [51]. Because the SCAN-B project has extraordinary supporting registries of clinical information, it is possible to make a true assessment of the frequency of BRCA1/BRCA2-deficient cancers in TNBC in the Swedish population (~59%), and to be able to ascertain that HRDetect has independent prognostic properties capable of discerning patients who will respond to standard-of-care from those that do not seem to gain any benefit from current treatments [51]. Furthermore, the WGS approach allows us to “see” other abnormalities in these breast cancers, some of which may be targetable with treatments that are otherwise not offered to women with breast cancer.

The example we provide above is one where we have reused large WGS datasets using machine-learning methods to develop a novel clinical algorithm, and then applied it to a clinical cohort in order to understand its true clinical value (fig. 2). Now rolled out into clinical trials, what we aim to do through the Josef Steiner Award is to build the infrastructure to allow us to perform these sorts of analyses more efficiently, to develop new algorithms as a result of having greater flexibility in exploring the data and to accelerate the translation of whole cancer genomics into the clinic.

**Holistic genome interpretation**

Today it is already possible to provide an individual WGS report in a matter of days, providing all the drivers, mutational signatures and even germline information for each patient. Novel algorithms can already provide clear readouts of HR deficiency and MMR deficiency. In due course, more exhaustive holistic WGS reports should provide therapeutically relevant treatment strategies associated with the genomic results too. Presently, what are the hurdles that prevent using WGS reporting for cancer today?

One of the first concerns about WGS was the cost of sequencing. With the precipitous decline in sequencing costs in the last decade, this is now something of a myth. The cost of WGS is today less than that of a contrast-enhanced computed tomography (CT) scan of the chest, abdomen

---

**Figure 2: Developing and translating clinical computational tools.** Having genomic and clinical data that are well-structured and organised is essential for the efficient development of novel clinical algorithms. Once putative clinical algorithms are developed, the critical next steps towards fully translating the algorithm is to apply it into retrospective and prospective clinical cohorts.
and pelvis. Yet this radiological test is performed routinely to gain the full anatomical picture of a patient’s disease status. Healthcare providers and medical insurance companies would not think twice about requesting or funding these investigations. Yet there is hesitation regarding WGS of solid tumours. There are admittedly additional costs associated with WGS, such as storage and backup of sequencing and intermediary files. Nevertheless, there is also added value. WGS data that are stored intelligently could serve as an ever-growing clinical research resource.

The second and more appropriate concern is the hurdle of analysis and interpretation. In this domain, however, there is substantial acceleration in how to perform WGS analysis and interpretation. Awards such as Steiner will certainly help our team to organise data and analyse it quickly to build more tools to assist in WGS interpretation.

Conclusions and future directions

It is quite possible, or even likely, that having a WGS for every (relevant) solid cancer will become a routine part of the diagnostic process for every patient within the next 10–20 years, if not sooner. There are already several large endeavours that have initiated WGS cancer sequencing research projects, including the 100,000 genomes project in the UK [52] and the Hartwig consortium in the Netherlands [53] among others. It is possible that these research projects will lead the way in transitioning into clinical practice. We should thus prepare for a future where WGS (or some form of genetics/transcriptomics) may become another assay like a set of bloods, an electrocardiogram, a staging CT scan or positron emission tomography scan, in the process of trying to comprehensively understand the patient’s cancer clinical picture.

To achieve this vision, first we must provide the infrastructure and support to train the next generation of molecular genomic interpreters, whether they are pathologists, geneticists or an altogether new breed of scientific/medical experts. Apart from computational support, we need to develop standard operating procedures for data handling and analysis, statistical and academic frameworks to operate from, and legal and/or ethical guidelines, to name a few areas of development. What they will learn to do is to read/interpret a whole cancer genome, like a radiologist would do for an X-ray or CT scan.

Second, clinical trials of chemotherapeutic agents that incorporate improved genomic profiling of tumours are required. This is not a trivial exercise and years of work are ahead of us before we will be in a position to match therapies to genomic status more effectively in the future.

Third, we must do the right thing by our future clinicians and scientists, which is to build the best infrastructure to support modern analytical methods. It is possible to structure data so that we maximise learning from every case going forward. The human genome is so vast and there is much that we do not yet understand. Genomic data are perfect for exploration using machine-learning methods, to develop artificial intelligence that will help the clinicians/scientists of the future with diagnostics. We must build the foundations to suit that future.

Financial disclosure

The authors are personally funded by the following grants: CRUK Advanced Clinician Scientist Award (C60100/A23916) and a CRUK Grand Challenge Award (C60100/A25274).

Potential competing interests

SNZ and HD are inventors on a number of encompassing the use of mutational signatures in specific clinical algorithms.

References


